A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over further exemplifying this trend. At the same time, the uptick in interest in radiopharmaceuticals has left supply chains struggling to meet demand with isotope producers scrambling to upscale capacity.
Attempts to increase patient access to these drugs is also exerting pressure on policy makers to revise the reimbursement and regulation of radiopharmaceuticals. Find out more. While Pluvicto is marketed for metastatic castration-resistant prostate cancer mCRPC , Lutathera is indicated for treating neuroendocrine gastroenteropancreatic tumours. Both are also in ongoing studies in other cancer settings. The appetite for radiopharmaceuticals has been reflected in moves made by some of the largest pharmaceutical companies in recent months.
As interest in radiopharmaceuticals has soared, supply chains have struggled to keep up. Isotope producers have responded well, says Dr. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form.
These shortages are an expected feature of sector growth according to Dr. However, as per Hermann, rather than isotope supply, patient access could prove the bottleneck for growth in this sector. Hinging largely on regulator and government attitudes, he notes regulatory heterogeneity around radiopharmaceuticals as a potential roadblock to further development. Pio argues that this trend is likely to continue for companies currently invested in the space who can leverage radiopharmaceutical capabilities to expand their nuclear medicine portfolios.
